Novavax, Inc. (NVAX) Revenue History
Novavax, Inc. (NVAX) annual revenue history. Get revenue data in Excel with MarketXLS.
Revenue Data
| Period | Revenue (USD) |
|---|---|
| 2016-12-31 | $15.35M |
| 2017-12-31 | $31.18M |
| 2018-12-31 | $34.29M |
| 2019-12-31 | $7.50M |
| 2020-12-31 | $475.60M |
| 2021-12-31 | $1.15B |
| 2022-12-31 | $1.98B |
| 2023-12-31 | $983.71M |
| 2024-12-31 | $682.16M |
| 2025-12-31 | $1.12B |
How NVAX compares with sector peers
| Symbol | Company | Revenue (latest fiscal year) |
|---|---|---|
| BCRX | BioCryst Pharmaceuticals Inc. | $874.84M |
| ARWR | Arrowhead Pharmaceuticals Inc. | $829.45M |
| MYGN | Myriad Genetics Inc. | $824.50M |
| USPH | U.S. Physical Therapy Inc. | $780.99M |
| EBS | Emergent BioSolutions Inc. | $742.90M |
These are five companies in the same sector as NVAX with a comparable annual revenue. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Novavax, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Revenue("NVAX", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | NVAX | $9.05 | -1.74% | 3.42M |
| 3 | ||||
| 4 | ||||
| 5 |